Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 18/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | KRAS | P01116 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PRNP | P04156 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL318332 | 0.85 | PTGDR2 (0.90) | PTGDR2PTGS1SLC6A4CYP2C9CYP2C19 | |
| SCHEMBL318388 | 0.82 | PTGDR2 (0.83) | PTGDR2PTGS1SLC6A4CYP2C9CYP2C19 | |
| SCHEMBL318694 | 0.81 | PTGDR2 (0.81) | PTGDR2PTGS1SLC6A4CYP2C9CYP2C19 | |
| SCHEMBL317636 | 0.79 | PTGDR2 (0.77) | PTGDR2PTGS1SLC6A4CYP2C9CYP2C19 | |
| SCHEMBL317216 | 0.79 | PTGDR2 (0.72) | PTGDR2PTGS1SLC6A4CYP2C9CYP2C19 | |
| SCHEMBL317387 | 0.79 | PTGDR2 (0.77) | PTGDR2PTGS1SLC6A4CYP2C9CYP2C19 | |
| SCHEMBL4893168 | 0.78 | PTGDR2 (0.50) | PTGDR2PTGS1KDM4EPRNPRXFP1 | |
| SCHEMBL317777 | 0.78 | PTGDR2 (0.76) | PTGDR2PTGS1SLC6A4CYP2C9CYP2C19 | |
| SCHEMBL317624 | 0.78 | PTGDR2 (0.68) | PTGDR2PTGS1SLC6A4CYP2C9CYP2C19 | |
| SCHEMBL317810 | 0.78 | PTGDR2 (0.76) | PTGDR2PTGS1SLC6A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027092-A1 | 1-Acetic Acid-Indole, -Indazole and -Benzimidazole Derivatives Useful for the Treatment of Respiratory Disorders | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | claimed |
| US-20080027092-A1 | 1-Acetic Acid-Indole, -Indazole and -Benzimidazole Derivatives Useful for the Treatment of Respiratory Disorders | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027092-A1 | 1-Acetic Acid-Indole, -Indazole and -Benzimidazole Derivatives Useful for the Treatment of Respiratory Disorders | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027092-A1 | 1-Acetic Acid-Indole, -Indazole and -Benzimidazole Derivatives Useful for the Treatment of Respiratory Disorders | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027092-A1 | 1-Acetic Acid-Indole, -Indazole and -Benzimidazole Derivatives Useful for the Treatment of Respiratory Disorders | IDO1, ABAT, ECI1 | PTGDR2 736/4885PTGS1 368/4885SLC6A4 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.